Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation

In conclusion, we determined the trough and peak levels of AFXaA in patients with NVAF while being treated with the apixa ban in Korea. Our results could be used as a starting point when setting the reference ranges for laboratories using anti-Xa assay. Large-scale studies are needed to establish the reference range for AFXaA in patients with NVAF.
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research